Immuno-Oncology Clinical Trials Market
Immuno-Oncology Clinical Trials Market - Global Industry Assessment & Forecast
#
Pages:
150
Base Year:
2022
Sep - 2023
Format:
Report Code:
VMR-2267
Segments Covered
By
Phase Phase I, Phase 2, Phase 3, Phase 4
-
By
Design Interventional Trials, Observational Trials, Expanded Access Trials
-
By
Indication Solid Tumors, Hematological Cancer, Other Indications
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 5.8 Billion |
 Revenue 2030:
|
USD 18.1 Billion |
 Revenue CAGR
(2023 - 2030): |
15.3% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Immuno-Oncology Clinical Trials Market Segment Analysis
- Immuno-Oncology Clinical Trials Phase Outlook (Revenue, USD Million, 2018 - 2030)
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Immuno-Oncology Clinical Trials Design Outlook (Revenue, USD Million, 2018 - 2030)
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Immuno-Oncology Clinical Trials Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Solid Tumors
- Hematological Cancer
- Other Indications
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
-
North America Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
-
North America Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- U.S.
- U.S. Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- U.S. Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- U.S. Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- U.S. Immuno-Oncology Clinical Trials Market, by Phase
- Canada
- Canada Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Canada Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Canada Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Canada Immuno-Oncology Clinical Trials Market, by Phase
-
Mexico
- Mexico Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Mexico Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Mexico Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Mexico Immuno-Oncology Clinical Trials Market, by Phase
-
North America Immuno-Oncology Clinical Trials Market, by Phase
- Europe
-
Europe Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
-
Europe Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
-
Europe Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- U. K.
- U.K. Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- U.K. Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- U.K. Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- U.K. Immuno-Oncology Clinical Trials Market, by Phase
- France
- France Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- France Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- France Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- France Immuno-Oncology Clinical Trials Market, by Phase
-
Germany
- Germany Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Germany Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Germany Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Germany Immuno-Oncology Clinical Trials Market, by Phase
-
Italy
- Italy Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Italy Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Italy Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Italy Immuno-Oncology Clinical Trials Market, by Phase
-
Spain
- Spain Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Spain Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Spain Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Spain Immuno-Oncology Clinical Trials Market, by Phase
-
Rest of Europe
- Rest of Europe Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Rest of Europe Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Rest of Europe Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Rest of Europe Immuno-Oncology Clinical Trials Market, by Phase
-
Europe Immuno-Oncology Clinical Trials Market, by Phase
- Asia Pacific
-
Asia Pacific Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
-
Asia Pacific Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
-
Asia Pacific Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- China
- China Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- China Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- China Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- China Immuno-Oncology Clinical Trials Market, by Phase
- Japan
- Japan Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Japan Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Japan Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Japan Immuno-Oncology Clinical Trials Market, by Phase
-
Germany
- Germany Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Germany Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Germany Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Germany Immuno-Oncology Clinical Trials Market, by Phase
-
India
- India Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- India Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- India Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- India Immuno-Oncology Clinical Trials Market, by Phase
-
South Korea
- South Korea Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- South Korea Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- South Korea Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- South Korea Immuno-Oncology Clinical Trials Market, by Phase
-
South East Asia
- South East Asia Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- South East Asia Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- South East Asia Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- South East Asia Immuno-Oncology Clinical Trials Market, by Phase
-
Rest of Asia Pacific
- Rest of Asia Pacific Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Rest of Asia Pacific Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Rest of Asia Pacific Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Rest of Asia Pacific Immuno-Oncology Clinical Trials Market, by Phase
-
Asia Pacific Immuno-Oncology Clinical Trials Market, by Phase
- Latin America
-
Latin America Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
-
Latin America Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
-
Latin America Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Brazil
- Brazil Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Brazil Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Brazil Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Brazil Immuno-Oncology Clinical Trials Market, by Phase
- Argentina
- Argentina Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Argentina Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Argentina Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Argentina Immuno-Oncology Clinical Trials Market, by Phase
-
Rest of Latin America
- Rest of Latin America Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Rest of Latin America Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Rest of Latin America Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Rest of Latin America Immuno-Oncology Clinical Trials Market, by Phase
-
Latin America Immuno-Oncology Clinical Trials Market, by Phase
- Middle East & Africa
-
Middle East & Africa Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
-
Middle East & Africa Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
-
Middle East & Africa Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- GCC Countries
- GCC Countries Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- GCC Countries Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- GCC Countries Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- GCC Countries Immuno-Oncology Clinical Trials Market, by Phase
- South Africa
- South Africa Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- South Africa Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- South Africa Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- South Africa Immuno-Oncology Clinical Trials Market, by Phase
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Immuno-Oncology Clinical Trials Market, by Phase
- Phase I
- Phase 2
- Phase 3
- Phase 4
- Rest of Middle East & Africa Immuno-Oncology Clinical Trials Market, by Design
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- Rest of Middle East & Africa Immuno-Oncology Clinical Trials Market, by Indication
- Solid Tumors
- Hematological Cancer
- Other Indications
- Rest of Middle East & Africa Immuno-Oncology Clinical Trials Market, by Phase
-
Middle East & Africa Immuno-Oncology Clinical Trials Market, by Phase
- North America
Vantage Market
Research | 06-Sep-2023
FAQ
Frequently Asked Question
What is the global demand for Immuno-Oncology Clinical Trials in terms of revenue?
-
The global Immuno-Oncology Clinical Trials valued at USD 5.8 Billion in 2022 and is expected to reach USD 18.1 Billion in 2030 growing at a CAGR of 15.3%.
Which are the prominent players in the market?
-
The prominent players in the market are ICON PLC (Ireland), IQVIA Holdings Inc. (U.S.), Covance (U.S.), BioNTech (Germany), IO Biotech Medical (Denmark), Medpace (U.S.), Novartis (Switzerland), Exscientia (UK), Syneous Health (U.S.), AstraZeneca (UK).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 15.3% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Immuno-Oncology Clinical Trials include
- Changes in lifestyle brought on by urbanization
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Immuno-Oncology Clinical Trials in 2022.
